The Pennant Group (PNTG)
(Delayed Data from NSDQ)
$28.60 USD
+0.60 (2.14%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $28.59 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.60 USD
+0.60 (2.14%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $28.59 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Zacks News
Take the Zacks Approach to Beat the Market: Annexon, NVIDIA, Intuit in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Investors Undervaluing The Pennant Group (PNTG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.
Should Value Investors Buy The Pennant Group (PNTG) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fast-paced Momentum Stock The Pennant Group, Inc. (PNTG) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, The Pennant Group, Inc. (PNTG) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's What Key Metrics Tell Us About The Pennant Group, Inc. (PNTG) Q3 Earnings
by Zacks Equity Research
The headline numbers for The Pennant Group, Inc. (PNTG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Encompass Health (EHC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 11.69% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should Value Investors Buy Encompass Health (EHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's What Key Metrics Tell Us About The Pennant Group, Inc. (PNTG) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for The Pennant Group, Inc. (PNTG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 12.50% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 28.38% and 2.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -7.47% and 1.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Misses Q1 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -13.33% and 3.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
New Strong Buy Stocks for April 17th
by Zacks Equity Research
IOT, PNTG, ACLX, ELUXY and AB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Why Fast-paced Mover The Pennant Group, Inc. (PNTG) Is a Great Choice for Value Investors
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.